[{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"GtCCR4","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Mitsubishi UFJ Capital"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"PPP003","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKI2S","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Ikarovec \/ UKI2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ UKI2S"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Horama SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"HORA-001","moa":"CRB1 gene","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Leiden University Medical Center \/ Horama SA","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Horama SA"},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"LGC Group GB \/ OliX Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group GB \/ OliX Pharmaceuticals"},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"ACRO Biomedical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mediprint Ophthalmics \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ PharmAbcine"},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Irvine School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Irvine School of Medicine \/ Not Applicable"},{"orgOrder":0,"company":"GelMEDIX","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GelMEDIX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Hydrogel Implant","sponsorNew":"GelMEDIX \/ HTL","highestDevelopmentStatusID":"1","companyTruncated":"GelMEDIX \/ HTL"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":1.8999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Pharmathen SA \/ Partners Group","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen SA \/ Partners Group"},{"orgOrder":0,"company":"Re-Vana Therapeutics","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Re-Vana Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Re-Vana Therapeutics \/ Visionary Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Re-Vana Therapeutics \/ Visionary Ventures"},{"orgOrder":0,"company":"Selagine","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Selagine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Selagine \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Selagine \/ Grifols International"},{"orgOrder":0,"company":"Ikarovec","sponsor":"Rentschler Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Ikarovec \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ Rentschler Biopharma"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Adeno-associated Virus Vector","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"4D Molecular Therapeutics","amount2":0.95999999999999996,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"4D Molecular Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"4D Molecular Therapeutics \/ Astellas Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Study Phase : Undisclosed

                          Sponsor : Partners Group

                          Deal Size : $1,900.0 million

                          Deal Type : Acquisition

                          Details : On acquisition, Partners Group will work to strengthen Pharmathen’s business in Europe and the US, especially R&D, sustained release’ technologies, including long-acting injectables, slow-releasing oral drugs and ophthalmics segment.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 19, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Partners Group

                          Deal Size : $1,900.0 million

                          Deal Type : Acquisition

                          Pharmathen

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : ADC-based Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Novelty Nobility

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Astellas gains rights to utilize the intravitreal retinotropic R100 adeno-associated virus vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic diseases, with options to add up to two additional targets implicated for th...

                          Brand Name : R100

                          Molecule Type : Large molecule

                          Upfront Cash : $20.0 million

                          July 10, 2023

                          Lead Product(s) : Adeno-associated Virus Vector

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Astellas Pharma

                          Deal Size : $962.5 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 01, 2023

                          Lead Product(s) : AAV-based Gene Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Rentschler Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Grifols will develop and commercialise immunoglobulin eye drops, SLG-100, for dry eye disease. An immunoglobulin eye drop is a biologic drug that contains naturally occurring functional antibodies generated from human plasma collected from thousands of h...

                          Brand Name : SLG-100

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 06, 2023

                          Lead Product(s) : SLG-100

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Grifols International

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The proceeds will advance the development of Re-Vana’s novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and will enable expansion of the company’s operations and development teams...

                          Brand Name : Undislosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 06, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Visionary Ventures

                          Deal Size : $11.9 million

                          Deal Type : Series A Financing

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the G...